Future marketing of ephedrine "street drugs" is "irresponsible," FDA tells six companies.
This article was originally published in The Tan Sheet
Executive Summary
CONTINUED MARKETING OF EPHEDRINE "STREET DRUGS" IS "IRRESPONSIBLE," FDA tells six companies in Aug. 19 letters. The letters target firms that manufacture or distribute ephedrine-containing street drug knock-offs that claim to "cause such effects as euphoria, increased sexual sensations, and/or heightened awareness."